“Tildrakizumab Efficacy by Metabolic Syndrome Status in Psoriasis: Post Hoc Analysis of 3-Year Data from the Phase 3 Resurface 1 And Resurface 2 Studies”. 2020. SKIN The Journal of Cutaneous Medicine 4 (5): s42. https://doi.org/10.25251/skin.4.supp.42.